California State Teachers Retirement System trimmed its holdings in DaVita Inc. (NYSE:DVA - Free Report) by 14.5% in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 38,704 shares of the company's stock after selling 6,539 shares during the quarter. California State Teachers Retirement System owned about 0.06% of DaVita worth $8,610,866 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors have also modified their holdings of the company. Fifth Third Bancorp lifted its stake in DaVita by 831.4% during the first quarter. Fifth Third Bancorp now owns 38,411 shares of the company's stock worth $5,903,000 after purchasing an additional 34,287 shares during the last quarter. Assenagon Asset Management S.A. grew its holdings in DaVita by 30.5% during the second quarter. Assenagon Asset Management S.A. now owns 44,783 shares of the company's stock valued at $9,963,000 after purchasing an additional 10,477 shares during the period. SG Americas Securities LLC boosted its position in DaVita by 27.4% during the first quarter. SG Americas Securities LLC now owns 212,293 shares of the company's stock valued at $32,627,000 after purchasing an additional 45,609 shares during the last quarter. Invst LLC acquired a new position in shares of DaVita during the 2nd quarter worth approximately $1,238,000. Finally, LSV Asset Management increased its holdings in DaVita by 1.1% in the 4th quarter. LSV Asset Management now owns 936,768 shares of the company's stock worth $106,426,000 after purchasing an additional 9,739 shares in the last quarter. 90.12% of the stock is currently owned by hedge funds and other institutional investors.
DaVita Price Performance
Shares of DVA stock traded up $1.05 on Tuesday, hitting $190.37. 262,968 shares of the company's stock were exchanged, compared to its average volume of 919,070. The stock has a market cap of $12.15 billion, a P/E ratio of 15.59, a price-to-earnings-growth ratio of 0.47 and a beta of 0.83. The company has a 50 day moving average of $203.10 and a 200 day moving average of $185.95. DaVita Inc. has a 12 month low of $101.00 and a 12 month high of $247.49.
DaVita (NYSE:DVA - Get Free Report) last released its quarterly earnings data on Tuesday, August 4th. The company reported $4.02 EPS for the quarter, topping the consensus estimate of $3.88 by $0.14. The company had revenue of $3.55 billion during the quarter, compared to the consensus estimate of $3.50 billion. DaVita had a net margin of 6.05% and a negative return on equity of 217.63%. DaVita's revenue for the quarter was up 5.2% on a year-over-year basis. During the same period last year, the firm earned $2.95 EPS. DaVita has set its FY 2026 guidance at 14.100-15.200 EPS. Sell-side analysts predict that DaVita Inc. will post 14.57 EPS for the current fiscal year.
Wall Street Analysts Forecast Growth
Several research analysts have recently weighed in on the stock. Raymond James Financial set a $220.00 price target on shares of DaVita in a report on Friday, August 7th. Truist Financial decreased their price objective on DaVita from $250.00 to $215.00 and set a "hold" rating for the company in a report on Friday, August 7th. Barclays increased their price target on DaVita from $218.00 to $224.00 and gave the company an "equal weight" rating in a report on Wednesday, August 5th. TD Cowen raised DaVita from a "hold" rating to a "buy" rating and upped their target price for the company from $201.00 to $220.00 in a research report on Friday, August 7th. Finally, Zacks Research downgraded DaVita from a "strong-buy" rating to a "hold" rating in a research report on Monday, July 6th. Four investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $233.43.
Read Our Latest Report on DVA
DaVita Company Profile
(
Free Report)
DaVita Inc NYSE: DVA is a healthcare company focused primarily on kidney care. Through its DaVita Kidney Care business, the company provides outpatient dialysis services for people with chronic kidney failure, including in-center hemodialysis and home-based dialysis options. Its services also include clinical care, education, nutrition support and other resources intended to help patients manage kidney disease.
DaVita also provides broader kidney-care services, including chronic kidney disease management, care coordination and support for patients who may be candidates for kidney transplantation.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider DaVita, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and DaVita wasn't on the list.
While DaVita currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.
